{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:04:32Z","timestamp":1770433472444,"version":"3.49.0"},"reference-count":42,"publisher":"American Association for Cancer Research (AACR)","issue":"23","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We previously mapped a nonrandom frequent loss of heterozygosity (LOH) region in cervical cancers to 1 Mb of 6p23. Here, we describe the identification of a novel cervical cancer susceptibility gene, CD83. The gene was identified by several complementary approaches, including a family-based association study, comparison of transcript expression in normal and cancerous tissue, and genomic sequencing of candidate. CD83 encodes an inducible glycoprotein in the immunoglobulin superfamily and is a marker for mature dendritic cells. The association study that includes 377 family trios showed that five single nucleotide polymorphisms (SNP) within 8 kb of its 3\u2032-end showed significant allelic association that was strengthened in a subgroup of women with invasive cancers infected by high-risk human papillomavirus type 16 and 18 (rs9296925, P = 0.0193; rs853360, P = 0.0035; rs9230, P = 0.0011; rs9370729, P = 0.0012; rs750749, P = 0.0133). Investigation of CD83 uncovered three alternative transcripts in cervical tissue and cell lines, with variant 3 (lacking exons 3 and 4) being more frequent in cervical cancer than in normal cervical epithelium (P = 0.0181). Genomic sequencing on 36 paired normal and cervical tumors revealed several somatic mutations and novel SNPs in the promoter, exons, and introns of CD83. LOH was confirmed in &amp;gt;90% of cervical cancer specimens. Immunofluorescence colocalized CD83 protein to the Golgi apparatus and cell membrane of cervical cancer cell lines. None of seven nearby genes was differentially expressed in cervical cancer. The importance of CD83 in epithelial versus dendritic cells needs to be determined, as does its role in promoting cervical cancer. [Cancer Res 2007;67(23):11202\u20138]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-2677","type":"journal-article","created":{"date-parts":[[2007,12,3]],"date-time":"2007-12-03T19:23:27Z","timestamp":1196709807000},"page":"11202-11208","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["<i>CD83<\/i> Gene Polymorphisms Increase Susceptibility to Human Invasive Cervical Cancer"],"prefix":"10.1158","volume":"67","author":[{"given":"Zhengyan","family":"Zhang","sequence":"first","affiliation":[{"name":"1Obstetrics and Gynecology, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Borecki","sequence":"additional","affiliation":[{"name":"2Genetics,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loan","family":"Nguyen","sequence":"additional","affiliation":[{"name":"1Obstetrics and Gynecology, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duanduan","family":"Ma","sequence":"additional","affiliation":[{"name":"2Genetics,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Smith","sequence":"additional","affiliation":[{"name":"1Obstetrics and Gynecology, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyllis C.","family":"Huettner","sequence":"additional","affiliation":[{"name":"3Pathology and Immunology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G.","family":"Mutch","sequence":"additional","affiliation":[{"name":"1Obstetrics and Gynecology, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas J.","family":"Herzog","sequence":"additional","affiliation":[{"name":"1Obstetrics and Gynecology, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall K.","family":"Gibb","sequence":"additional","affiliation":[{"name":"1Obstetrics and Gynecology, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Powell","sequence":"additional","affiliation":[{"name":"1Obstetrics and Gynecology, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Perry W.","family":"Grigsby","sequence":"additional","affiliation":[{"name":"4Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Stewart","family":"Massad","sequence":"additional","affiliation":[{"name":"5Department of Obstetrics and Gynecology, Southern Illinois University School of Medicine, Springfield, Illinois;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Hernandez","sequence":"additional","affiliation":[{"name":"6Department of Obstetrics, Gynecology and Reproductive Sciences, Temple University School of Medicine, Philadelphia, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia L.","family":"Judson","sequence":"additional","affiliation":[{"name":"7Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota Medical School, Minneapolis, Minnesota;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth M.","family":"Swisher","sequence":"additional","affiliation":[{"name":"8Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Crowder","sequence":"additional","affiliation":[{"name":"9Mid-Missouri Gynecologic Oncology, Columbia, Missouri"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianduan","family":"Li","sequence":"additional","affiliation":[{"name":"1Obstetrics and Gynecology, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela S.","family":"Gerhard","sequence":"additional","affiliation":[{"name":"2Genetics,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet S.","family":"Rader","sequence":"additional","affiliation":[{"name":"1Obstetrics and Gynecology, Departments of"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2007,12,3]]},"reference":[{"key":"2022061623192811000_B1","doi-asserted-by":"crossref","unstructured":"Saslow D, Castle PE, Cox JT, et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin\u20082007; 57: 7\u201328.","DOI":"10.3322\/canjclin.57.1.7"},{"key":"2022061623192811000_B2","doi-asserted-by":"crossref","unstructured":"Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst\u20082005; 97: 1072\u20139.","DOI":"10.1093\/jnci\/dji187"},{"key":"2022061623192811000_B3","doi-asserted-by":"crossref","unstructured":"Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer\u20082002; 2: 59\u201365.","DOI":"10.1038\/nrc700"},{"key":"2022061623192811000_B4","doi-asserted-by":"crossref","unstructured":"Magnusson PK, Sparen P, Gyllensten UB. Genetic link to cervical tumours. Nature\u20081999; 400: 29\u201330.","DOI":"10.1038\/21801"},{"key":"2022061623192811000_B5","doi-asserted-by":"crossref","unstructured":"Wang SS, Hildesheim A. Chapter 5: viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr\u20082003; 31: 35\u201340.","DOI":"10.1093\/oxfordjournals.jncimonographs.a003480"},{"key":"2022061623192811000_B6","doi-asserted-by":"crossref","unstructured":"Neuman RJ, Huettner PC, Li L, et al. Association between DQB1 and cervical cancer in patients with human papillomavirus and family controls. Obstet Gynecol\u20082000; 95: 134\u201340.","DOI":"10.1016\/S0029-7844(99)00501-3"},{"key":"2022061623192811000_B7","doi-asserted-by":"crossref","unstructured":"Orth G. Genetics of epidermodysplasia verruciformis: insights into host defense against papillomaviruses. Semin Immunol\u20082002; 18: 362\u201374.","DOI":"10.1016\/j.smim.2006.07.008"},{"key":"2022061623192811000_B8","doi-asserted-by":"crossref","unstructured":"Fitzpatrick MA, Funk MC, Gius D, et al. Identification of chromosomal alterations important in the development of cervical intraepithelial neoplasia and invasive carcinoma using alignment of DNA microarray data. Gynecol Oncol\u20082006; 103: 458\u201362.","DOI":"10.1016\/j.ygyno.2006.03.020"},{"key":"2022061623192811000_B9","doi-asserted-by":"crossref","unstructured":"Zhang Z, Gerhard DS, Nguyen L, et al. Fine mapping and evaluation of candidate genes for cervical cancer on 11q23. Genes Chromosomes Cancer\u20082005; 43: 95\u2013103.","DOI":"10.1002\/gcc.20151"},{"key":"2022061623192811000_B10","doi-asserted-by":"crossref","unstructured":"Umayahara K, Numa F, Suehiro Y, et al. Comparative genomic hybridization detects genetic alterations during early stages of cervical cancer progression. Genes Chromosomes Cancer\u20082002; 33: 98\u2013102.","DOI":"10.1002\/gcc.1215"},{"key":"2022061623192811000_B11","doi-asserted-by":"crossref","unstructured":"Rader JS, Gerhard DS, O'Sullivan MJ, et al. Cervical intraepithelial neoplasia III shows frequent allelic loss in 3p and 6p. Genes Chromosomes Cancer\u20081998; 22: 57\u201365.","DOI":"10.1002\/(SICI)1098-2264(199805)22:1<57::AID-GCC8>3.0.CO;2-6"},{"key":"2022061623192811000_B12","unstructured":"Rader JS, Kamarasova T, Huettner PC, et al. Allelotyping of all chromosomal arms in invasive cervical cancer. Oncogene\u20081996; 13: 2737\u201341."},{"key":"2022061623192811000_B13","doi-asserted-by":"crossref","unstructured":"Rader JS, Li Y, Huettner PC, Xu Z, Gerhard DS. Cervical cancer suppressor gene is within 1 cM on 6p23. Genes Chromosomes Cancer\u20082000; 27: 373\u20139.","DOI":"10.1002\/(SICI)1098-2264(200004)27:4<373::AID-GCC6>3.0.CO;2-V"},{"key":"2022061623192811000_B14","doi-asserted-by":"crossref","unstructured":"de Bakker PI, Yelensky R, Pe'er I, et al. Efficiency and power in genetic association studies. Nat Genet\u20082005; 37: 1217\u201323.","DOI":"10.1038\/ng1669"},{"key":"2022061623192811000_B15","doi-asserted-by":"crossref","unstructured":"Chang YE, Pena L, Sen GC, Park JK, Laimins LA. Long-term effect of interferon on keratinocytes that maintain human papillomavirus type 31. J Virol\u20082002; 76: 8864\u201374.","DOI":"10.1128\/JVI.76.17.8864-8874.2002"},{"key":"2022061623192811000_B16","doi-asserted-by":"crossref","unstructured":"Zhang Z, Huettner PC, Nguyen L, et al. Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer. Oncogene\u20082006; 25: 5436\u201345.","DOI":"10.1038\/sj.onc.1209530"},{"key":"2022061623192811000_B17","doi-asserted-by":"crossref","unstructured":"Klein E, Koch S, Borm B, et al. CD83 localization in a recycling compartment of immature human monocyte-derived dendritic cells. Int Immunol\u20082005; 17: 477\u201387.","DOI":"10.1093\/intimm\/dxh228"},{"key":"2022061623192811000_B18","doi-asserted-by":"crossref","unstructured":"Li J, Gerhard DS, Zhang Z, et al. Denaturing high-performance liquid chromatography for detecting and typing genital human papillomavirus. J Clin Microbiol\u20082003; 41: 5563\u201371.","DOI":"10.1128\/JCM.41.12.5563-5571.2003"},{"key":"2022061623192811000_B19","doi-asserted-by":"crossref","unstructured":"Clayton D, Jones H. Transmission\/disequilibrium tests for extended marker haplotypes. Am J Hum Genet\u20081999; 65: 1161\u20139.","DOI":"10.1086\/302566"},{"key":"2022061623192811000_B20","doi-asserted-by":"crossref","unstructured":"Skol AD, Scott LJ, Abecasis GR, Boehnke M. Optimal designs for two-stage genome-wide association studies. Genet Epidemiol\u20082007; 31: 776\u201388.","DOI":"10.1002\/gepi.20240"},{"key":"2022061623192811000_B21","doi-asserted-by":"crossref","unstructured":"Wright JD, Li J, Gerhard DS, et al. Human papillomavirus type and tobacco use as predictors of survival in early stage cervical carcinoma. Gynecol Oncol\u20082005; 98: 84\u201391.","DOI":"10.1016\/j.ygyno.2005.03.038"},{"key":"2022061623192811000_B22","doi-asserted-by":"crossref","unstructured":"Burger RA, Monk BJ, Kurosaki T, et al. Human papillomavirus type 18: association with poor prognosis in early stage cervical cancer. J Natl Cancer Inst\u20081996; 88: 1361\u20138.","DOI":"10.1093\/jnci\/88.19.1361"},{"key":"2022061623192811000_B23","doi-asserted-by":"crossref","unstructured":"Okazaki Y, Furuno M, Kasukawa T, et al. Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature\u20082002; 420: 563\u201373.","DOI":"10.1038\/nature01266"},{"key":"2022061623192811000_B24","doi-asserted-by":"crossref","unstructured":"Waterston RH, Lindblad-Toh K, Birney E, et al. Initial sequencing and comparative analysis of the mouse genome. Nature\u20082002; 420: 520\u201362.","DOI":"10.1038\/nature01262"},{"key":"2022061623192811000_B25","doi-asserted-by":"crossref","unstructured":"Hasina R, Pontier AL, Fekete MJ, et al. NOL7 is a nucleolar candidate tumor suppressor gene in cervical cancer that modulates the angiogenic phenotype. Oncogene\u20082006; 25: 588\u201398.","DOI":"10.1038\/sj.onc.1209070"},{"key":"2022061623192811000_B26","doi-asserted-by":"crossref","unstructured":"Gius D, Funk MC, Chuang EY, et al. Profiling microdissected epithelium and stroma to model genomic signatures for cervical carcinogenesis accommodating for covariates. Cancer Res\u20082007; 67: 7113\u201323.","DOI":"10.1158\/0008-5472.CAN-07-0260"},{"key":"2022061623192811000_B27","doi-asserted-by":"crossref","unstructured":"Zhao H. Family-based association studies. Stat Methods Med Res\u20082000; 9: 563\u201387.","DOI":"10.1177\/096228020000900604"},{"key":"2022061623192811000_B28","doi-asserted-by":"crossref","unstructured":"Lechmann M, Zinser E, Golka A, Steinkasserer A. Role of CD83 in the immunomodulation of dendritic cells. Int Arch Allergy Immunol\u20082002; 129: 113\u20138.","DOI":"10.1159\/000065883"},{"key":"2022061623192811000_B29","doi-asserted-by":"crossref","unstructured":"Breloer M, Kretschmer B, Luthje K, et al. CD83 is a regulator of murine B cell function in vivo. Eur J Immunol\u20082007; 37: 634\u201348.","DOI":"10.1002\/eji.200636852"},{"key":"2022061623192811000_B30","doi-asserted-by":"crossref","unstructured":"Garcia-Martinez LF, Appleby MW, Staehling-Hampton K, et al. A novel mutation in CD83 results in the development of a unique population of CD4+ T cells. J Immunol\u20082004; 173: 2995\u20133001.","DOI":"10.4049\/jimmunol.173.5.2995"},{"key":"2022061623192811000_B31","doi-asserted-by":"crossref","unstructured":"Scholler N, Hayden-Ledbetter M, Dahlin A, et al. Cutting edge: CD83 regulates the development of cellular immunity. J Immunol\u20082002; 168: 2599\u2013602.","DOI":"10.4049\/jimmunol.168.6.2599"},{"key":"2022061623192811000_B32","doi-asserted-by":"crossref","unstructured":"Luthje K, Cramer SO, Ehrlich S, et al. Transgenic expression of a CD83-immunoglobulin fusion protein impairs the development of immune-competent CD4-positive T cells. Eur J Immunol\u20082006; 36: 2035\u201345.","DOI":"10.1002\/eji.200636068"},{"key":"2022061623192811000_B33","doi-asserted-by":"crossref","unstructured":"Fujimoto Y, Tu L, Miller AS, et al. CD83 expression influences CD4+ T cell development in the thymus. Cell\u20082002; 108: 755\u201367.","DOI":"10.1016\/S0092-8674(02)00673-6"},{"key":"2022061623192811000_B34","doi-asserted-by":"crossref","unstructured":"Lechmann M, Krooshoop DJ, Dudziak D, et al. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J Exp Med\u20082001; 194: 1813\u201321.","DOI":"10.1084\/jem.194.12.1813"},{"key":"2022061623192811000_B35","doi-asserted-by":"crossref","unstructured":"Senechal B, Boruchov AM, Reagan JL, Hart DN, Young JW. Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood\u20082004; 103: 4207\u201315.","DOI":"10.1182\/blood-2003-12-4350"},{"key":"2022061623192811000_B36","doi-asserted-by":"crossref","unstructured":"Berchtold S, Muhl-Zurbes P, Maczek E, et al. Cloning and characterization of the promoter region of the human CD83 gene. Immunobiology\u20082002; 205: 231\u201346.","DOI":"10.1078\/0171-2985-00128"},{"key":"2022061623192811000_B37","doi-asserted-by":"crossref","unstructured":"Dudziak D, Kieser A, Dirmeier U, et al. Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-\u03baB signaling pathway. J Virol\u20082003; 77: 8290\u20138.","DOI":"10.1128\/JVI.77.15.8290-8298.2003"},{"key":"2022061623192811000_B38","doi-asserted-by":"crossref","unstructured":"Prechtel AT, Chemnitz J, Schirmer S, et al. Expression of CD83 is regulated by HuR via a novel cis-active coding region RNA element. J Biol Chem\u20082006; 281: 10912\u201325.","DOI":"10.1074\/jbc.M510306200"},{"key":"2022061623192811000_B39","doi-asserted-by":"crossref","unstructured":"Dudziak D, Nimmerjahn F, Bornkamm GW, Laux G. Alternative splicing generates putative soluble CD83 proteins that inhibit T cell proliferation. J Immunol\u20082005; 174: 6672\u20136.","DOI":"10.4049\/jimmunol.174.11.6672"},{"key":"2022061623192811000_B40","doi-asserted-by":"crossref","unstructured":"Andersen JM, Al-Khairy D, Ingalls RR. Innate immunity at the mucosal surface: role of toll-like receptor 3 and toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol Reprod\u20082006; 74: 824\u201331.","DOI":"10.1095\/biolreprod.105.048629"},{"key":"2022061623192811000_B41","doi-asserted-by":"crossref","unstructured":"Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diagn Lab Immunol\u20082001; 8: 209\u201320.","DOI":"10.1128\/CDLI.8.2.209-220.2001"},{"key":"2022061623192811000_B42","doi-asserted-by":"crossref","unstructured":"zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer\u20082002; 2: 342\u201350.","DOI":"10.1038\/nrc798"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/23\/11202\/2576757\/11202.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/23\/11202\/2576757\/11202.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T02:20:04Z","timestamp":1655432404000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/23\/11202\/533853\/CD83-Gene-Polymorphisms-Increase-Susceptibility-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,1]]},"references-count":42,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2007,12,3]]},"published-print":{"date-parts":[[2007,12,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-2677","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,1]]}}}